Downloaded 380 times
Uploaded byhospital
DELIVER delivered 2022.pptx
The study randomized 6263 heart failure patients with left ventricular ejection fraction over 40% to receive either dapagliflozin or placebo alongside usual therapy. The primary outcome measured was the incidence of worsening heart failure or cardiovascular death. Findings indicated that serious adverse events were reported similarly between dapagliflozin and placebo groups, highlighting the potential of SGTL2 inhibitors in managing heart failure.
More Related Content
Similar to DELIVER delivered 2022.pptx
DELIVER delivered 2022.pptx
- 1. Dapagliflozin in HeartFailure with Mildly Reduced or Preserved Ejection Fraction List of authors.Scott D. Solomon, M.D., John J.V. McMurray, M.D., Brian Claggett, Ph.D., Rudolf A. de Boer, M.D., David DeMets, Ph.D., Adrian F. Hernandez, M.D., Silvio E. Inzucchi, M.D., Mikhail N. Kosiborod, M.D., Carolyn S.P. Lam, M.D., Felipe Martinez, M.D., Sanjiv J. Shah, M.D., Akshay S. Desai, M.D., et al., for the DELIVER Trial Committees and Investigators DELIVER 27/8/2022 NEJM
- 3. METHODS • We randomlyassigned 6263 patients with heart failure and a left ventricular ejection fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in addition to usual therapy. • The primary outcome was a composite of worsening heart failure (which was defined as either an unplanned hospitalization for heart failure or an urgent visit for heart failure) or cardiovascular death, as assessed in a time-to- event analysis.
- 4. • Sodium–glucose cotransporter2 (SGLT2) inhibitors, which were originally developed as glucose-lowering agents for the treatment of type 2 diabetes mellitus, reduce the risk of death and other adverse outcomes among patients with chronic heart failure and a reduced ejection fraction (i.e., a left ventricular ejection fraction of ≤40%) and in those with chronic kidney disease, regardless of the presence or absence of type 2 diabetes mellitus.
- 5. • Current clinicalguidelines strongly recommend the use of SGLT2 inhibitors in patients with chronic heart failure and a reduced ejection fraction.
- 13. SAFETY • Overall, seriousadverse events, including death, were reported in 1361 patients (43.5%) in the dapagliflozin group and in 1423 patients (45.5%) in the placebo group . • Adverse events that led to discontinuation of dapagliflozin or placebo were reported in 182 patients (5.8%) in the dapagliflozin group and in 181 patients (5.8%) in the placebo group.